Patents Assigned to Greystone Medical Group, Inc.
  • Publication number: 20100196507
    Abstract: A synthesized composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when applied to an open wound, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method for treatment of wounds is disclosed.
    Type: Application
    Filed: September 23, 2009
    Publication date: August 5, 2010
    Applicant: GREYSTONE MEDICAL GROUP, INC.
    Inventors: Stephen H. MONROE, Matthias Johannes HOEKSTRA
  • Publication number: 20060105017
    Abstract: A method for treatment of wounds associated with the insertion of a medical implant, wherein an inorganic therapeutic agent containing potassium, rubidium, calcium and zinc cations is applied to the wound site on a silicone or bioabsorbable membrane. The therapeutic composition is provided in a long lasting, timed delivery formulation to improve the efficacy of the therapeutic agent. The membrane may contain a micro-texture to further control delivery of the therapeutic agent to the wound site.
    Type: Application
    Filed: June 22, 2005
    Publication date: May 18, 2006
    Applicant: GREYSTONE MEDICAL GROUP, INC.
    Inventors: Xaverius Walboomers, Matthias Hoekstra, J. Jansen
  • Patent number: 7014870
    Abstract: Higher concentrations of oak bark ash extract, i.e., greater than 20% by weight, are useful for the treatment of skin cancers. Lower concentrations of oak bark extract possess additional therapeutic properties not heretofore recognized. For example, preparations containing 40–80% oak bark extract are useful in the treatment of acute cancerous skin ulcers. In addition, synthetic mixtures containing potassium ions, zinc ions, calcium ions provide many of the same advantageous properties of oak bark extract. The inclusion of rubidium ions and sulfur is also advantageous for some applications.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: March 21, 2006
    Assignee: Greystone Medical Group, Inc.
    Inventors: David N.-S Hon, R. Thomas Stanley
  • Publication number: 20040170703
    Abstract: Reactive oxygen species associated with a wound are modulated through treatment of the wound with a solution of metal ions selected from the group consisting of potassium ions, zinc ions, calcium ions and rubidium ions, at a pH of between about 5 and about 7. Preferably, citric acid is employed to adjust the pH of the solution. Application of the extract to a wound exhibiting superoxide anions has been found to be effective in the treatment of these wounds through the reduction of the level of superoxide anions. Moreover, treatment of partial thickness excision wounds as well as contact burn wounds with the present composition has been found to improve epithelialization of these wounds. In addition to the antioxidant activity of the present invention, treatment of the wound employing the present composition produces inhibitory effects on ROS production by human PMNs and on human complement activation, and therefore, is further beneficial in chronic wound management.
    Type: Application
    Filed: December 23, 2003
    Publication date: September 2, 2004
    Applicant: Greystone Medical Group, Inc.
    Inventors: Hans Hoekstra, Stephen H. Monroe, A. J. J. Van Den Berg
  • Publication number: 20040105897
    Abstract: A synthesized composition containing one or more of zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when administered to a patient in need thereof, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method is disclosed.
    Type: Application
    Filed: August 21, 2003
    Publication date: June 3, 2004
    Applicant: Greystone Medical Group, Inc.
    Inventors: Stephen H. Monroe, Hans Hoekstra
  • Publication number: 20040023937
    Abstract: Composition for halting the metastasis of cancer cells comprising rubidum ursolate. The rubidium ursolate is formed from a mixture of rubidium and ursolic acid obtained from the bark of the Virburnum plant.
    Type: Application
    Filed: May 22, 2003
    Publication date: February 5, 2004
    Applicant: Greystone Medical Group, Inc.
    Inventor: Stephen H. Monroe
  • Publication number: 20030133991
    Abstract: A synthesized composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when applied to an open wound, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method for treatment of wounds is disclosed.
    Type: Application
    Filed: November 27, 2002
    Publication date: July 17, 2003
    Applicant: Greystone Medical Group, Inc.
    Inventors: Stephen H. Monroe, Hans Hoekstra
  • Patent number: 6149947
    Abstract: Higher concentrations of oak bark ash extract, i.e., greater than 20% by weight, are useful for the treatment of skin cancers. Lower concentrations of oak bark extract possess additional therapeutic properties not heretofore recognized. For example, preparations containing 40-80% oak bark extract are useful in the treatment of acute cancerous skin ulcers. In addition, synthetic mixtures containing potassium ions, zinc ions, calcium ions provide many of the same advantageous properties of oak bark extract. The inclusion of rubidium ions and sulfur is also advantageous for some applications.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: November 21, 2000
    Assignee: Greystone Medical Group, Inc.
    Inventors: David N.-S Hon, R. Thomas Stanley